MOTS-c vs Elamipretide
MOTS-c therapeutic administration remains largely preclinical; elamipretide has extensive human development and a specific FDA-approved Barth-syndrome product/indication.
| Attribute | MOTS-c | Elamipretide |
|---|---|---|
| Human evidence | Human studies show endogenous MOTS-c biology during exercise, and a genuine randomized Phase 2a trial of administered subcutaneous MOTS-c is recruiting in adults with prediabetes and overweight/obesity; no efficacy results are posted yet. | Elamipretide has multiple human trials. In primary mitochondrial myopathy, small early studies showed signals but the 218-person Phase III MMPOWER-3 trial missed both co-primary endpoints. Barth syndrome follows a separate rare-disease evidence and regulatory pathway and should not be generalized to wellness use. |
| Research focus | Metabolism, exercise physiology, ageing biology | Mitochondrial disease; Barth syndrome; broader mitochondrial research |
| Regulatory status | Not FDA-approved; FDA highlights absence of human drug-product exposure data. | Forzinity (elamipretide) received FDA accelerated approval for Barth syndrome patients ≥30 kg; this does not make generic SS-31 vials approved. |
| Route / formulation | Endogenous exercise-induced MOTS-c measurements are not evidence that injected MOTS-c is effective or safe. | Generic SS31 research products are not equivalent to Forzinity and may differ in quality/formulation. |
Why these are compared
These compounds appear in the mitochondrial / energy research evidence landscape, but they are not interchangeable. MOTS-c is mitochondrial-derived 16-amino-acid peptide studied in metabolism, exercise physiology, ageing biology; Elamipretide is mitochondria-targeted tetrapeptide studied in mitochondrial disease; barth syndrome; broader mitochondrial research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
MOTS-c: Human trial underway; no published administered-drug efficacy result.
Elamipretide: PMM Phase III negative; FDA accelerated approval for narrow Barth syndrome indication.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head human trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.